Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26658594 | 1.00 | MEN1 (0.37) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL26658421 | 1.00 | MEN1 (0.37) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11762827 | 0.87 | MEN1 (0.38) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL4386275 | 0.85 | MEN1 (0.35) | MEN1KMT2AKDM4C | |
| SCHEMBL4386281 | 0.85 | MEN1 (0.35) | MEN1KMT2AKDM4C | |
| SCHEMBL27039533 | 0.84 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL31661105 | 0.84 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL27039534 | 0.84 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL16309245 | 0.82 | MEN1 (0.34) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL12916612 | 0.82 | MEN1 (0.34) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-16 | — | — | US | disclosed |
| WO-2023220577-A1 | 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-11-16 | — | — | WO | disclosed |
| US-8344163-B2 | Nitrile compound and its use for control of arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20110021627-A1 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2265569-A2 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | Sumitomo Chemical Company, Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009116687-A2 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021627-A1 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | C5, OR10J3, NOX3 | MEN1 439/4885KMT2A 2101/4885KDM4C 188/4885 |
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | MEN1 910/4885KMT2A 4133/4885KDM4C 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.